To assess the relative efficacies of aspirin and sulfinpyrazone in the treatment of patients with TIA.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
- Sulfinpyrazone (Anturane)Drug
Intervention Desc: Uricosuric agent, platelet inhibitor, antithrombotic agent.
Stratified, randomized, double-blind trial of 124 patients at 6 centers. Patients were stratified by center.
Patients were randomized to receive aspirin (500 mg twice daily) or sulfinpyrazone (400 mg twice daily). Follow-up visits were scheduled 1, 2, 4, and 6 months after commencement of treatment and every three months thereafter for a maximum of two years.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Stroke, myocardial infarction, vascular death, and worsening or no improvement of TIAs.|